Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6410465 | 0.99 | CCR3 (0.49) | CCR3SIGMAR1HSD11B1MEN1KMT2A | |
| SCHEMBL6409199 | 0.89 | CCR3 (0.51) | CCR3SIGMAR1MEN1KMT2ALTA4H | |
| SCHEMBL6411384 | 0.89 | KMT2A (0.58) | CCR3SIGMAR1MEN1KMT2ALTA4H | |
| SCHEMBL6409303 | 0.88 | CCR3 (0.61) | CCR3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6415973 | 0.88 | KMT2A (0.57) | CCR3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6412416 | 0.88 | CCR3 (0.50) | CCR3SIGMAR1MEN1KMT2ALTA4H | |
| SCHEMBL6408894 | 0.88 | CCR3 (0.50) | CCR3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6408480 | 0.87 | CCR3 (0.60) | CCR3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6408795 | 0.87 | CCR3 (0.49) | CCR3SIGMAR1MEN1KMT2A | |
| SCHEMBL6412927 | 0.85 | CCR3 (0.50) | CCR3SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR3 13/4885SIGMAR1 277/4885HSD11B1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.